<AdverseEventReport><id>49</id><createdAt xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">2008-11-26 16:37:25.772</createdAt><status xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">PENDING</status><AdverseEventResponseDescription><eventDescription>test</eventDescription><presentStatus xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">INTERVENTION_CONTINUES</presentStatus><retreated>false</retreated><autopsyPerformed>false</autopsyPerformed><primaryTreatmentApproximateTime><type>0</type></primaryTreatmentApproximateTime></AdverseEventResponseDescription><Physician><firstName>r</firstName><lastName>r</lastName><address/><ContactMechanism xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:org.exolab.castor.mapping.MapItem"><key xsi:type="java:java.lang.String">phone</key><value xsi:type="java:java.lang.String">0000000000</value></ContactMechanism><ContactMechanism xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:org.exolab.castor.mapping.MapItem"><key xsi:type="java:java.lang.String">e-mail</key><value xsi:type="java:java.lang.String">karthik.iyer@semanticbits.com</value></ContactMechanism></Physician><Reporter><firstName>r</firstName><lastName>r</lastName><address/><ContactMechanism xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:org.exolab.castor.mapping.MapItem"><key xsi:type="java:java.lang.String">phone</key><value xsi:type="java:java.lang.String">0000000000</value></ContactMechanism><ContactMechanism xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:org.exolab.castor.mapping.MapItem"><key xsi:type="java:java.lang.String">fax</key><value xsi:type="java:java.lang.String">0000000000</value></ContactMechanism><ContactMechanism xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:org.exolab.castor.mapping.MapItem"><key xsi:type="java:java.lang.String">e-mail</key><value xsi:type="java:java.lang.String">karthik.iyer@semanticbits.com</value></ContactMechanism></Reporter><DiseaseHistory><diagnosisDate><dayString>01</dayString><monthString>10</monthString><yearString>2008</yearString></diagnosisDate><CtepStudyDisease><id>1</id><leadDisease>true</leadDisease><DiseaseTerm><id>24</id><term>Glioblastoma multiforme</term><ctepTerm>Glioblastoma multiforme</ctepTerm><DiseaseCategory><id>16</id><name>Astrocytoma, High Grade</name></DiseaseCategory></DiseaseTerm></CtepStudyDisease><AnatomicSite><id>3</id><name>Peripheral blood</name><category>Bone Marrow</category></AnatomicSite><MetastaticDiseaseSite><id>17</id><AnatomicSite><id>10</id><name>Appendix</name><category>Gastrointestinal</category></AnatomicSite></MetastaticDiseaseSite></DiseaseHistory><ParticipantHistory><height><quantity>1</quantity><unit>Centimeter</unit></height><weight><quantity>1</quantity><unit>Kilogram</unit></weight><baselinePerformanceStatus>3 = Symptomatic, in bed more than 50% of time</baselinePerformanceStatus></ParticipantHistory><StudyParticipantAssignment><dateOfEnrollment>2008-09-29T00:00:00.000-04:00</dateOfEnrollment><StudySite><StudyInvestigator><id>1</id><roleCode>Site Investigator</roleCode><statusCode>Active</statusCode><SiteInvestigator><id>133</id><Investigator><id>125</id><firstName>John</firstName><lastName>Fiveash</lastName><nciIdentifier>30537</nciIdentifier><emailAddress>default@abc.com</emailAddress><phoneNumber>(000)000-0000</phoneNumber><faxNumber>(000)000-0000</faxNumber></Investigator></SiteInvestigator></StudyInvestigator><Study><id>1</id><multiInstitutionIndicator>true</multiInstitutionIndicator><shortTitle>Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme</shortTitle><longTitle>A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme</longTitle><description>A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiformexxxx</description><phaseCode>Phase I Trial</phaseCode><primarySponsorCode>CTEP</primarySponsorCode><status>Active - Trial is open to accrual</status><Ctc><id>3</id><name>CTCAE v3.0</name></Ctc><Identifier><type>Protocol Authority Identifier</type><value>N027D</value><primaryIndicator>true</primaryIndicator></Identifier><Identifier><type>Coordinating Center Identifier</type><value>N027D</value><primaryIndicator>false</primaryIndicator></Identifier><StudyAgent><Agent><id>228</id><name>CCI-779 (temsirolimus, Torisel)</name><nscNumber>683864</nscNumber></Agent><INDType xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">CTEP_IND</INDType></StudyAgent><StudyAgent><Agent><id>1083</id><name>Temozolomide</name><nscNumber>362856</nscNumber></Agent><INDType xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">NA_COMMERCIAL</INDType></StudyAgent><CtepStudyDisease><id>1</id><leadDisease>true</leadDisease><DiseaseTerm><id>24</id><term>Glioblastoma multiforme</term><ctepTerm>Glioblastoma multiforme</ctepTerm><DiseaseCategory><id>16</id><name>Astrocytoma, High Grade</name></DiseaseCategory></DiseaseTerm></CtepStudyDisease></Study><Organization><id>101418</id><name>University of Alabama at Birmingham</name><nciInstituteCode>AL002</nciInstituteCode><SiteInvestigator><id>91</id><Investigator><id>86</id><firstName>Bruce</firstName><lastName>Korf</lastName><nciIdentifier>32049</nciIdentifier><emailAddress>default@abc.com</emailAddress><phoneNumber>(000)000-0000</phoneNumber><faxNumber>(000)000-0000</faxNumber></Investigator></SiteInvestigator><SiteInvestigator><id>133</id><Investigator><id>125</id><firstName>John</firstName><lastName>Fiveash</lastName><nciIdentifier>30537</nciIdentifier><emailAddress>default@abc.com</emailAddress><phoneNumber>(000)000-0000</phoneNumber><faxNumber>(000)000-0000</faxNumber></Investigator></SiteInvestigator></Organization></StudySite><Participant><firstName>Kristopher</firstName><lastName>Cane</lastName><dateOfBirth><monthString>01</monthString><yearString>1963</yearString></dateOfBirth><gender>Male</gender><race>Not Reported</race><ethnicity>Hispanic or Latino</ethnicity><Identifier><type>MRN</type><value>id-1</value><primaryIndicator>true</primaryIndicator></Identifier><Identifier><type>MRN</type><value>aaa</value><primaryIndicator>false</primaryIndicator></Identifier></Participant><studySubjectIdentifier>ctep-phI</studySubjectIdentifier></StudyParticipantAssignment><RadiationIntervention><id>8</id><dosage>123</dosage><dosageUnit>mCi</dosageUnit><lastTreatmentDate>2009-01-01T00:00:00.000-05:00</lastTreatmentDate><fractionNumber>2</fractionNumber><daysElapsed>1</daysElapsed><adjustment>Continue Radiation as planned</adjustment><administration xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">BT_HDR</administration></RadiationIntervention><ConcomitantMedication><name>conmed 1</name><startDate/><endDate/><stillTakingMedications>false</stillTakingMedications></ConcomitantMedication><AdverseEvent><gridId>PRY8fcb3cd9-4dd4-4480-8595-f2a1f9d52524</gridId><startDate>2008-11-26T00:00:00.000-05:00</startDate><expected>false</expected><ConcomitantMedicationAttribution><id>156</id><attribution xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">4: Probable</attribution><ConcomitantMedication><name>conmed 1</name><startDate/><endDate/><stillTakingMedications>false</stillTakingMedications></ConcomitantMedication></ConcomitantMedicationAttribution><CourseAgentAttribution><id>155</id><attribution xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">4: Probable</attribution><CourseAgent><id>41</id><lastAdministeredDate>2008-11-26T00:00:00.000-05:00</lastAdministeredDate><Dose><amount>1</amount><units>BVP</units></Dose><StudyAgent><Agent><id>228</id><name>CCI-779 (temsirolimus, Torisel)</name><nscNumber>683864</nscNumber></Agent><INDType xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">CTEP_IND</INDType></StudyAgent></CourseAgent></CourseAgentAttribution><DiseaseAttribution><id>157</id><attribution xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">3: Possible</attribution><DiseaseHistory><id>49</id><diagnosisDate><dayString>01</dayString><monthString>10</monthString><yearString>2008</yearString></diagnosisDate><CtepStudyDisease><id>1</id><leadDisease>true</leadDisease><DiseaseTerm><id>24</id><term>Glioblastoma multiforme</term><ctepTerm>Glioblastoma multiforme</ctepTerm><DiseaseCategory><id>16</id><name>Astrocytoma, High Grade</name></DiseaseCategory></DiseaseTerm></CtepStudyDisease><AnatomicSite><id>3</id><name>Peripheral blood</name><category>Bone Marrow</category></AnatomicSite><MetastaticDiseaseSite><id>17</id><AnatomicSite><id>10</id><name>Appendix</name><category>Gastrointestinal</category></AnatomicSite></MetastaticDiseaseSite></DiseaseHistory></DiseaseAttribution><RadiationAttribution><id>248</id><attribution xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">2: Unlikely</attribution><RadiationIntervention><id>8</id><dosage>123</dosage><dosageUnit>mCi</dosageUnit><lastTreatmentDate>2009-01-01T00:00:00.000-05:00</lastTreatmentDate><fractionNumber>2</fractionNumber><daysElapsed>1</daysElapsed><adjustment>Continue Radiation as planned</adjustment><administration xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">BT_HDR</administration></RadiationIntervention></RadiationAttribution><AdverseEventCtcTerm other-required="false" med-dRA="false"><ctc-term><id>3001</id><term>Allergic reaction/hypersensitivity (including drug fever)</term><ctepTerm>Hypersensitivity</ctepTerm><ctepCode>10020751</ctepCode><otherRequired>false</otherRequired><CtcCategory><id>301</id><name>ALLERGY/IMMUNOLOGY</name></CtcCategory></ctc-term><universal-term>Allergic reaction/hypersensitivity (including drug fever)</universal-term><term xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="CtcTerm"><id>3001</id><term>Allergic reaction/hypersensitivity (including drug fever)</term><ctepTerm>Hypersensitivity</ctepTerm><ctepCode>10020751</ctepCode><otherRequired>false</otherRequired><CtcCategory><id>301</id><name>ALLERGY/IMMUNOLOGY</name></CtcCategory></term><full-name>Allergic reaction/hypersensitivity (including drug fever)</full-name></AdverseEventCtcTerm><AdverseEventMeddraLowLevelTerm/><attributionSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">4: Probable</attributionSummary><grade xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">4: Life-threatening or disabling</grade><hospitalization xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">1: Yes</hospitalization><eventApproximateTime><type>0</type></eventApproximateTime><Outcome><id>117</id><OutcomeType xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">HOSPITALIZATION</OutcomeType></Outcome></AdverseEvent><SAEReportPriorTherapy><id>48</id><PriorTherapy><id>12</id><text>Image Directed Local Therapy</text><meddraTerm>90003016</meddraTerm></PriorTherapy><startDate/><endDate/></SAEReportPriorTherapy><SAEReportPriorTherapy><id>49</id><PriorTherapy><id>13</id><text>No prior therapy</text><meddraTerm>10052052</meddraTerm><meddraCode>No previous exposure to drug NOS</meddraCode></PriorTherapy><startDate/><endDate/></SAEReportPriorTherapy><SAEReportPriorTherapy><id>50</id><PriorTherapy><id>9</id><text>Gene Transfer</text><meddraTerm>90003004</meddraTerm></PriorTherapy><startDate/><endDate/></SAEReportPriorTherapy><SAEReportPriorTherapy><id>51</id><PriorTherapy><id>5</id><text>Chemotherapy multiple agents systemic</text><meddraTerm>10008452</meddraTerm><meddraCode>Chemotherapy multiple agents systemic</meddraCode></PriorTherapy><startDate/><endDate/><PriorTherapyAgent><id>4</id><ChemoAgent><name>Hexalen</name></ChemoAgent></PriorTherapyAgent></SAEReportPriorTherapy><Summary id="Participant"><value>Kristopher Cane (id-1)</value></Summary><Summary id="Study"><value>Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme (N027D)</value></Summary><Summary id="Report created at"><value>2008-11-26 16:37:25.772</value></Summary><Summary id="Primary AE"><value>Allergic reaction/hypersensitivity (including drug fever)</value></Summary><Summary id="AE count"><value>1</value></Summary><Summary id="Public identifier"><value>AL002-AL002</value></Summary><Summary id="Ticket number"/><Summary id="Next report due"/><TreatmentInformation><firstCourseDate>2008-11-26T00:00:00.000-05:00</firstCourseDate><TreatmentAssignment><code>A0</code><description>Concomitant Treatment      Cycle = 6 weeks:    CCI-779:  25mg/wk IV over 30 min weekly RT:  200cGy 5 days a wk, starting 7-10 days after first CCI-779 dose TMZ:  75mg/m2 PO QD with RT  Adjuvant Treatment     Cycle = 28 days     (Max = 6 cycles) CCI-779:</description></TreatmentAssignment><totalCourses>1</totalCourses><AdverseEventCourse><number>1</number><date>2008-11-26T00:00:00.000-05:00</date></AdverseEventCourse><CourseAgent><id>41</id><lastAdministeredDate>2008-11-26T00:00:00.000-05:00</lastAdministeredDate><Dose><amount>1</amount><units>BVP</units></Dose><StudyAgent><Agent><id>228</id><name>CCI-779 (temsirolimus, Torisel)</name><nscNumber>683864</nscNumber></Agent><INDType xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="java:java.lang.String">CTEP_IND</INDType></StudyAgent></CourseAgent></TreatmentInformation><SAEReportPreExistingCondition><id>28</id><PreExistingCondition><id>2</id><text>Autoimmune disorder</text></PreExistingCondition></SAEReportPreExistingCondition><AdditionalInformation><id>49</id><autopsyReport>false</autopsyReport><consults>false</consults><dischargeSummary>false</dischargeSummary><flowCharts>false</flowCharts><labReports>false</labReports><obaForm>false</obaForm><other>false</other><pathologyReport>false</pathologyReport><progressNotes>false</progressNotes><radiologyReports>false</radiologyReports><referralLetters>false</referralLetters><irbReport>false</irbReport></AdditionalInformation></AdverseEventReport>